HC Wainwright set a $11.00 target price on Correvio Pharma (NASDAQ:CORV) in a report released on Wednesday. The firm currently has a buy rating on the stock.
Several other research analysts have also recently issued reports on CORV. Mackie upgraded Correvio Pharma from a hold rating to a buy rating in a research report on Friday, October 12th. ValuEngine upgraded Correvio Pharma from a hold rating to a buy rating in a research report on Thursday, September 6th.
NASDAQ:CORV traded down $0.25 during trading hours on Wednesday, hitting $3.15. The company’s stock had a trading volume of 141,214 shares, compared to its average volume of 194,255. The stock has a market capitalization of $127.75 million, a price-to-earnings ratio of -3.50 and a beta of -0.08. The company has a debt-to-equity ratio of 4.02, a quick ratio of 3.49 and a current ratio of 4.05. Correvio Pharma has a 52-week low of $1.29 and a 52-week high of $5.24.
Correvio Pharma (NASDAQ:CORV) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.20). The firm had revenue of $7.01 million during the quarter, compared to analysts’ expectations of $7.55 million. Correvio Pharma had a negative return on equity of 294.35% and a negative net margin of 68.98%. On average, analysts predict that Correvio Pharma will post -1 EPS for the current year.
An institutional investor recently bought a new position in Correvio Pharma stock. Putnam Investments LLC acquired a new position in Correvio Pharma Corp (NASDAQ:CORV) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,092,133 shares of the company’s stock, valued at approximately $11,688,000. 45.41% of the stock is owned by institutional investors and hedge funds.
Correvio Pharma Company Profile
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.
Recommended Story: Call Option
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.